hVIVO PLC
HVO
Company Profile
Business description
hVIVO PLC is a European-focused, rare, and orphan drug consulting services platform. The principal activity of the Group is that of a rapidly growing specialist CRO pharmaceutical services company, which is involved in the testing of vaccines and antivirals using human-challenge clinical trials. The group is also engaged in Venn Life Sciences’ Clinical Research Division, providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations.
Contact
40 Bank Street
Floor 24
LondonE14 5NR
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
299
Stocks News & Analysis
stocks
ResMed earnings: Solid showing from ASX healthcare winner
Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.
stocks
Is this the $80 billion elephant Warren Buffett has been waiting for?
Morningstar’s Greg Warren says Berkshire may have little choice but to take a hard look at this huge potential acquisition.
stocks
Tesla: Board announces new pay package for CEO Elon Musk
A key provision of the new award is that Musk must remain in a senior leadership position at Tesla.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,018.20 | 96.20 | 1.08% |
| CAC 40 | 7,632.01 | 85.85 | 1.14% |
| DAX 40 | 23,757.69 | 331.72 | 1.42% |
| Dow JONES (US) | 44,173.64 | 585.06 | 1.34% |
| FTSE 100 | 9,128.30 | 59.72 | 0.66% |
| HKSE | 24,799.67 | 66.22 | 0.27% |
| NASDAQ | 21,053.58 | 403.45 | 1.95% |
| Nikkei 225 | 40,549.93 | 259.23 | 0.64% |
| NZX 50 Index | 12,857.29 | 173.25 | 1.37% |
| S&P 500 | 6,329.94 | 91.93 | 1.47% |
| S&P/ASX 200 | 8,760.80 | 97.10 | 1.12% |
| SSE Composite Index | 3,602.13 | 18.82 | 0.53% |